Dated primary sources
FDA & Regulatory Watch
Regulatory developments recorded with the date they were checked and a link to the issuing agency, so a reader can tell a current position from a stale one.
An advisory meeting is not an approval. Committee recommendations are non-binding, and a compound being discussed by a regulator does not make it approved, legal to sell, or safe to use. Each page below records what was decided, on what date, with a link to the agency’s own document.
- In review
BPC-157 Availability and Legal Status: What “Legal” Actually Means
A careful explanation of BPC-157’s lack of FDA approval, the 2026 compounding review, online “research use only” products, and why regulatory status cannot be reduced to a yes-or-no purchasing question.
FDA approval: Not FDA-approved
Reviewed September 2, 2026
- In review
FDA’s July 2026 Peptide Meeting: What Happened—and What Did Not
A source-based recap of the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting, the peptide-related substances discussed, and why an advisory recommendation is not FDA approval or blanket legalization.
Meeting: July 23–24, 2026
Reviewed September 2, 2026